Celularity Inc. (NASDAQ:CELU) Short Interest Update

Celularity Inc. (NASDAQ:CELU) was the recipient of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 743,700 shares, an increase of 9.3% from the October 15th total of 680,500 shares. Based on an average daily volume of 876,800 shares, the days-to-cover ratio is currently 0.8 days. Currently, 6.9% of the shares of the company are sold short.

Celularity Stock Up 9.3 %

CELU stock traded up $0.21 during trading on Friday, hitting $2.46. 4,624,191 shares of the company’s stock traded hands, compared to its average volume of 2,911,333. Celularity has a 52 week low of $1.30 and a 52 week high of $7.97. The stock has a fifty day moving average price of $2.55 and a two-hundred day moving average price of $2.88.

Celularity (NASDAQ:CELU) last announced its quarterly earnings data on Wednesday, October 16th. The company reported ($1.03) earnings per share for the quarter. Celularity had a negative net margin of 264.30% and a negative return on equity of 92.48%. The business had revenue of $14.68 million for the quarter.

Institutional Trading of Celularity

A hedge fund recently bought a new stake in Celularity stock. Keynote Financial Services LLC bought a new position in Celularity Inc. (NASDAQ:CELU) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 15,566 shares of the company’s stock, valued at approximately $81,000. Keynote Financial Services LLC owned 0.08% of Celularity at the end of the most recent reporting period. 19.02% of the stock is currently owned by hedge funds and other institutional investors.

About Celularity

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.